Liver cancer:Targeted future options
Liver cancer:Targeted future options作者机构：Department for Hematology and OncologyMedical University InnsbruckAnichstr.35Innsbruck 6020 Austria Hematology DepartmentUniversity Hospital BaselPetersgraben 4Basel 4031Switzerland Department for Internal MedicineHematology and OncologyGemeinschaftskrankenhaus HerdeckeGerhard-Kienle-Weg 4Herdecke 58313Germany
出 版 物：《World Journal of Hepatology》 (世界肝病学杂志（英文版）（电子版）)
年 卷 期：2011年第3卷第2期
页 面：38-44页
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题：Angiogenesis Epidermal growth factor receptor Hepatocellular carcinoma Targeted therapy Vascular endothelial growth factor
摘 要：Hepatocellular carcinoma(HCC)has a poor prognosis an d systemic chemotherapies have disappointing *** increasing knowledge of the molecular biolog y of HCC has resulted in novel targets,with the vascular endothelial growth factor and epidermal growth factor receptor(EGFR)-related pathways being of special *** blood vessel formation(angiogenesis)is essential for the growth of solid ***-angiogenic strategies have become an important therapeutic modality for solid *** agents targeting angiogenesis-related pathways have entered clinical trials or have been already approved for the treatment of solid *** include monoclonal antibodies,receptor tyrosine kinase inhibitors and immunomodulatory *** is a highly vascular tumor,and angiogenesis is be-lieved to play an important role in its development and *** review summarizes recent advances in the basic understanding of the role of angiogenesis in HCC as well as clinical trials with novel therapeutic approaches targeting angiogenesis and EGFR-related pathways.
维普期刊数据库